Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.

Author: BatemanKirk M, ComstockTimothy L, DecoryHeleen H, GearingerMatthew, PaternoMichael R

Paper Details 
Original Abstract of the Article :
Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T) is indicated for steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. LE/T was shown to be safe in healthy volunteers and patients age...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.2165/11596320-000000000-00000

データ提供:米国国立医学図書館(NLM)

Loteprednol Etabonate and Tobramycin: A Safe and Effective Option for Pediatric Ocular Conditions

Eye infections and inflammation can be particularly challenging in children. This research investigates the safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T), a combination medication used to treat steroid-responsive inflammatory ocular conditions in patients with potential bacterial infection. The study focuses on evaluating the safety of LE/T in pediatric subjects.

A Safe Haven for Little Eyes: Evaluating the Safety of LE/T

The study found that LE/T was generally safe and well-tolerated in pediatric subjects, with minimal impact on intraocular pressure (IOP). These findings suggest that LE/T could be a safe and effective treatment option for pediatric patients with steroid-responsive inflammatory ocular conditions.

Navigating the Desert of Eye Infections: Finding Safe and Effective Treatments

This research provides valuable information for healthcare providers treating pediatric patients with ocular conditions. The study suggests that LE/T is a promising treatment option, offering a safe and effective way to manage these challenging conditions. It's like finding a safe oasis in the desert of eye infections, providing relief and improving the well-being of young patients.

Dr.Camel's Conclusion

This study provides reassuring evidence of the safety and tolerability of LE/T in pediatric patients. This research offers hope for finding effective and safe treatment options for children experiencing eye infections and inflammation, helping them navigate the desert of ocular challenges with greater comfort and confidence.

Date :
  1. Date Completed 2013-03-29
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22292487

DOI: Digital Object Identifier

10.2165/11596320-000000000-00000

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.